Meropenem in the treatment of complicated skin and soft tissue infections

Therapeutics and Clinical Risk Management

Volumn 2, Issue 4, 2006, Pages 401-415

  Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antibiotics; Carbapenems; Diabetic foot; Meropenem; Nosocomial infection; Wound infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; ERTAPENEM; LINEZOLID; MEROPENEM; METICILLIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

AREA UNDER THE CURVE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PENICILLIN RESISTANCE; PSEUDOMONAS AERUGINOSA; REVIEW; SEIZURE; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT DURATION;

EID: 33845460167     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.4.401     Document Type: Review

References (74)

1. Alvarez-Lerma F; ICU-Acquired Pneumonia Study Group. 1996. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med, 22:387-94.
2. AstraZeneca Pharmaceuticals. 2006. MYSTIC surveillance study online database [online]. Accessed on 21 April 2006. URL: http://www.mystic-data.org/main.htm.
3. Bowler PG, Duerden BI, Armstrong DG. 2001. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev, 14:244-69.
4. Breedt J, Teras J, Gardovskis J, et al. 2005. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother, 49:4658-66.
5. Bukharie H, Abdelhadi M, Saeed I, et al. 2001. Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen. Diagn Microbiol Infect Dis, 40:1-4.
6. Bush K. 2001. New - lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis, 32:1085-9.
7. Carmeli Y, Troillet N, Karchmer AW, et al. 1999. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med, 159:1127-32.
8. [CDCP] Centers for Disease Control and Prevention. 2001. Incidence of soft tissue infections: San Francisco General Hospital - 1996-2000. Morbid Mortal Weekly Report, 50:381-4.
9. Chow JW, Satishchandran V, Snyder TA, et al. 2006. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect, 6:439-47.
10. Colardyn F, Faulkner KL. 1996. Intravenous meropenem versus imipenem/ cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother, 38:523-37.
11. Colsky AS, Kirsner RS, Kerdel FA. 1998. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface. Arch Dermatol, 134:1006-9.
12. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis, 26:1-10.
13. DiNubile M J, Lipsky BA. 2004. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother, 53(Suppl S2):ii37-ii50.
14. Doern GV, Jones RN, Pfaller MA, et al. 1999. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis, 34:65-72.
15. [DPH] US Department of Public Health and Human Services, Public Health Service. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control, 32:470-85.
16. Eady EA, Cove JH. 2003. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus - an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis, 16:103-24.
17. Embil JM, Iaconis J, Soto N, et al. 2005. Complicated skin and skin structure infections (cSSSI) in diabetic patients: bacteriology and clinical efficacy of meropenem (MEM) and imipenem-cilastatin (IPM) [abstract]. 45th Annual Meeting of the American Society for Microbiology, Washington, DC. 16-19 December. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2306.
18. Eron LJ, Lipsky BA, Low DE, et al. 2003. Managing skin and soft tissue infections; expert panel recommendations on key decision points. J Antimicrob Chemother, 52(Suppl. S1):i3-i17.
19. Fabian TC, File TM Jr, Embil JM, et al. 2005. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect, 6:269-82.
20. Falagas ME, Barefoot L, Griffith J, et al. 1996. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis, 15:913-21.
21. Fish DN, Singletary TJ. 1997. Meropenem: a new carbapenem antibiotic. Pharmacother, 17:644-69.
22. Fridkin SK, Hagerman JC, Morrison M, et al. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med, 352:1436-44.
23. Fuchs PC, Barry AL, Brown SD. 2001. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother, 45: 1915-18.
24. Fung HB, Chang JY, Kuczynski S. 2003. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs, 63:1459-80.
25. Garau J, Blanquer J, Cobo L, et al. 1997. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis, 16:789-96.
26. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. 2003. Impact of adequate empiric antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med, 31:2742-51.
27. Graham DR, Lucasti C, Malafaia O, et al. 2002. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Inf Dis, 34:1460-8.
28. Grayson ML, Gibbons GW, Habershaw GM, et al. 1994. Use of ampicillin/ sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infectious in diabetic patients. Clin Infect Dis, 18:683-93.
29. Hecht DW. 2004. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis, 39:92-7.
30. Hutchison M, Faulkner KL, Turner PJ, et al. 1995. A compilation of meropenem tissue distribution data. J Antimicrob Chemother, 36(Suppl A):43-56.
31. Jodrá VM, Pérez CD, Soler LS, et al. 2006. Results of the Spanish national nosocomial infection surveillance network (VICONOS) for surgery patients from January 1997 through December 2003. Am J Infect Control, 34:134-41.
32. Jones ME, Schmitz FJ, Fluit AC, et al. 1999. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an international surveillance program. Eur J Clin Microbiol Infect Dis, 18:403-8.
33. Jones ME, Karlowsky JA, Draghi DC, et al. 2003. Epidemiology and antibiotic susceptibility patterns of pathogens isolated from skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents, 22:406-19.
34. Karlowsky JA, Draghi DC, Jones ME, et al. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumanii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother, 47:1681-8.
35. Kollef MH, Sherman G, Ward S, et al. 1999. inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest, 115:462-74.
36. Kuti JL, Nightingale CH, Nicolan DP. 2004. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother, 48:2464-70.
37. Lami JL, Wilson SE, Hopkins JA. 1991. Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. Am Surg, 57:769-74.
38. Leibovici L, Shraga I, Drucker M, et al. 1998. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med, 244:379-86.
39. Lipsky BA, Berendt AR, Deery HG, et al. 2004. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis, 39:885-910.
40. Lipsky BA, Armstrong DG, Citron DM, et al. 2005. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicentre trial. Lancet, 366:1695-703.
41. Livermore DM, Carter MW, Bagel S, et al. 2001. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother, 45:1860-7.
42. Luna CM, Vujacich P, Niederman MS, et al. 1997. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest, 111:676-85.
43. Maglio D, Teng R, Thyrum PT, et al. 2003. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid. Antimicrob Agents Chemother, 47:1771-3.
44. Masterton RG, Kuti JL, Turner PJ, et al. 2005. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother, 55:71-7.
45. Merrem (meropenem) product package insert. 2005 (October). AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA.
46. Mouton JW, Van Den Anker JN. 1995. Meropenem clinical pharmacokinetics. Clin Pharmacokinet, 28:275-86.
47. Mutnick AH, Rhomberg PR, Sader HS, et al. 2004. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999-2001). J Antimicrob Chemother, 53:290-6.
48. Neuhanser MM, Weinstein RA, Rydman R, et al. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units. Implications for fluoroquinolone use. JAMA, 289:885-8.
49. Nichols RL. 1999. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother, 44:19-23.
50. Nichols RL, Smith JW, Geckler RW, et al. 1995. Meropenem versus imipenem/ cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J, 88:397-404.
51. Norrby SR, Gildon KM. 1999. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis, 31:3-10.
52. Ong CT, Kuti JL, Nicolau DP. 2005. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA program. Surg Infect, 6:419-26.
53. Paterson DL, Mulazimoglu L, Casellas JM, et al. 2000. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis, 30:473-8.
54. Paterson DL, Ko W-C, Von Gottberg A, et al. 2003. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum -lactamases. Clin Infect Dis, 39:31-7.
55. Pellizzer G, Strazzabosco M, Presi S, et al. 2001. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med, 18:822-7.
56. Pfaller MA, Segreti J. 2006. Overview of the epidemiological profile and laboratory detection of extended-spectrum -lactamases. Clin Infect Dis, 42(Suppl 4):S153-63.
57. Quale J, Bratu S, Gupta J, et al. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother, 50:1633-41.
58. Raghavan M, Linden PK. 2004. Newer treatment options for skin and soft tissue infections. Drugs, 64:1621-42.
59. Red Book. 2005. Medical Economics Company, Inc. Montvale, NJ, USA.
60. Rello J, Ausina V, Ricart M, et al. 1993. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest, 104:1230-5.
61. Rennie RP, Jones RN, Mutnick AH, et al. 2003. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis, 45:287-93.
62. Rhomberg PR, Fritsche TR, Sader HS, et al. 2005. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC Surveillance Program in the United States (2004). J Chemother, 17:459-69.
63. Sader HS, Jones RN, Silva JB, et al. 2002. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis, 44:281-8.
64. Stevens DL, Bisno AL, Chambers HF, et al. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis, 41:1373-406.
65. Swartz MN. 2000. Cellulitis and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone. p 1037-57.
66. Tan JS, Wishnow RM, Talan DA, et al. 1993. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother, 37:1580-6.
67. Tassler H, Cullmann W, Elhardt D. 1993. Therapy of soft tissue infections with piperacillin/tazobactam, J Antimicrob Chemother, 31(Suppl A):105-12.
68. Teppler H, Gesser RM, Friedland IR, et al. 2004. Safety and tolerability of ertapenem, J Antimicrob Chemother, 53(Suppl S2):ii75-ii81.
69. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin Infect Dis, 27:10-22.
70. Vinh DC, Embil JM. 2005. Rapidly progressive soft tissue infections. Lancet Infect Dis, 5:501-13.
71. Wilcox MH. 2005. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections. J Chemother, 17 (Suppl 1):23-9.
72. Wilson MA. 2003. Skin and soft-tissue infections: impact of resistant gram-positive bacteria. Am J Surg, 186 (Suppl 5A):35S-41S.
73. Wiseman LR, Wagstaff AJ, Brogden RN, et al. 1995. Meropenem: a review of its antibacterial activity, pharmacokinetic properties, and clinical efficacy. Drugs, 50:73-101.
74. Zervos MJ, Hershberger E, Nicolau DP, et al. 2003. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis, 37:1643-8.